CP and Alzheimer disease: Overall, existing meta-analyses in AD provided results of decreased levels of copper in the brain [31], along with a non-ceruloplasmin copper increase in serum/plasma [28,29,30,32,33], that accounts for copper excess in the bloodstream [34], in line with a number of clinical studies (Table 1).